Piper Sandler analyst Adam Maeder raised the firm’s price target on Inspire Medical to $305 from $300 and keeps an Overweight rating on the shares. The company reported Q4 results with sales at the high-end of the preannouncement and earnings materially better than forecasts, the analyst tells investors in a research note. Piper says Inspire "brings substantial momentum into the new year" and it continues to view the stock as its favorite name in 2023.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on INSP:
- Inspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Guidance
- Inspire Medical reports Q4 EPS 10c, consensus (57c)
- Inspire Medical price target raised to $310 from $308 at Truist
- CVRx initiated with a Buy at Lake Street
- Inspire Medical price target raised to $300 from $285 at Piper Sandler
